Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata

    September 2016 in “JCI insight
    Julian Mackay-Wiggan, Ali Jabbari, Nhan Nguyen, Jane E. Cerise, Charlotte Clark, Grace Ulerio, Megan Furniss, Roger Vaughan, Angela M. Christiano, Raphael Clynes
    Image of study
    TLDR Ruxolitinib effectively regrows hair in most patients with severe hair loss.
    In a pilot study from 2016, researchers tested the effectiveness of oral ruxolitinib, a JAK1/2 inhibitor, on 12 patients with moderate-to-severe alopecia areata (AA). The patients took 20 mg of ruxolitinib twice daily for 3-6 months, with a follow-up period of 3 months after discontinuation. The study reported that 75% (9 out of 12) of the patients experienced significant hair regrowth, with an average of 92% hair regrowth by the end of the treatment period. No serious adverse effects were reported, and gene expression analysis showed a decrease in inflammatory markers and an increase in hair-specific markers. The study concluded that ruxolitinib was effective in treating AA, but emphasized the need for larger, randomized controlled trials to confirm its safety and efficacy.
    View this study on insight.jci.org →

    Cited in this study